Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
|
|
ReportsActivation of the PI3K Pathway in Cancer Through Inhibition of PTEN by Exchange Factor P-REX2a
PTEN (phosphatase and tensin homolog on chromosome 10) is a tumor suppressor whose cellular regulation remains incompletely understood. We identified phosphatidylinositol 3,4,5-trisphosphate RAC exchanger 2a (P-REX2a) as a PTEN-interacting protein. P-REX2a mRNA was more abundant in human cancer cells and significantly increased in tumors with wild-type PTEN that expressed an activated mutant of PIK3CA encoding the p110 subunit of phosphoinositide 3-kinase subunit
1 Institute for Cancer Genetics and Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St. Nicholas Avenue, New York, NY 10032, USA. (PI3K ). P-REX2a inhibited PTEN lipid phosphatase activity and stimulated the PI3K pathway only in the presence of PTEN. P-REX2a stimulated cell growth and cooperated with a PIK3CA mutant to promote growth factor–independent proliferation and transformation. Depletion of P-REX2a reduced amounts of phosphorylated AKT and growth in human cell lines with intact PTEN. Thus, P-REX2a is a component of the PI3K pathway that can antagonize PTEN in cancer cells.
2 Department of Pathology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA. 3 Division of Pediatric Oncology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA. 4 Department of Medicine, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA. * To whom correspondence should be addressed. E-mail: rep15{at}columbia.edu
The editors suggest the following Related Resources on Science sites:In Science Signaling
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
|
Science. ISSN 0036-8075 (print), 1095-9203 (online)